Full Text View
Tabular View
No Study Results Posted
Related Studies
The Role of Calcipotriol as Radioprotector of Skin
This study is not yet open for participant recruitment.
Study NCT00445250   Information provided by Rabin Medical Center
First Received: March 7, 2007   No Changes Posted
This Tabular View shows the required WHO registration data elements as marked by

March 7, 2007
March 7, 2007
 
Prevention of radiodermatitis
Same as current
No Changes Posted
Side effects of Calcipotriol
Same as current
 
The Role of Calcipotriol as Radioprotector of Skin
Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.

Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast. To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.

STUDY PROTOCOL Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:

  1. . an assessment by a physician and a nurse according to the RTOG score (6).

    As follows:

    Grade 0 – no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 – extensive moist peeling, pitting edema. Grade 4 – ulcers, bleeding and necrosis.

  2. . A questionnaire to each patient regarding the efficacy and safety of the cream.
  3. . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment.

Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.

The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.

INCLUSION CRITERIA

  1. . Age ranging from 18 to 75.
  2. . Confirmed histological diagnosis of Breast cancer.
  3. . Radiotherapy treatment to the breast following lumpectomy.

EXCLUSION CRITERIA

  1. . Scleroderma.
  2. . An extremely large breast. Interfiled above 25 cm.
  3. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. . Mastectomy.
Phase II
Interventional
Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Radiodermatitis
Drug: Calcipotriol
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Not yet recruiting
50
 
 

Inclusion Criteria:

  1. Age ranging from 18 to 75.
  2. Confirmed histological diagnosis of Breast cancer.
  3. Radiotherapy treatment to the breast following lumpectomy.

Exclusion Criteria:

  1. Scleroderma.
  2. An extremely large breast. Interfiled above 25 cm.
  3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. Mastectomy.
Female
18 Years to 75 Years
No
Contact: Eyal Fenig, M.D. 97239377964 efenig@clalit.org.il
Contact: Ofer Purim, M.D. 97239377973 oferp@clalit.org.il
Israel
 
 
NCT00445250
 
 
Rabin Medical Center
 
Principal Investigator: Eyal Fenig, M.D. Rabin Medical Center
Rabin Medical Center
January 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.